Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Nanobiotix S.A. is a clinical-stage biotechnology company focused on the development of novel nanotechnology-based therapies for oncology. The company operates within the biopharmaceutical and oncology therapeutics industries, with a primary emphasis on improving the efficacy of radiation therapy through proprietary nanoparticle technology. Its core product candidate, NBTXR3 (also known as Hensify), is designed to enhance the local effect of radiotherapy in solid tumors by increasing tumor cell destruction without increasing damage to surrounding healthy tissue.
Founded in 2003 and headquartered in France, Nanobiotix was established to translate advances in nanomedicine into clinically meaningful cancer treatments. Over time, the company has evolved from a research-focused entity into a late-stage clinical development organization, with multiple ongoing clinical trials across different cancer indications. Nanobiotix is publicly listed on Euronext Paris and NASDAQ under the ticker NBTX, reflecting its dual European and U.S. market orientation.
Business Operations
Nanobiotix’s operations are centered on the research, development, and potential commercialization of its nanoparticle-based radioenhancer platform. The company reports a single primary operating segment focused on oncology drug development, with revenue historically derived from collaboration agreements, licensing arrangements, and research funding rather than product sales. Its lead asset, NBTXR3, is being evaluated in combination with radiotherapy and, in some trials, with immunotherapies.
The company conducts clinical development globally and controls proprietary nanoparticle manufacturing and formulation technologies. Its U.S. operations are conducted through its wholly owned subsidiary Nanobiotix Inc., which supports clinical development, regulatory engagement, and strategic partnerships in the United States. Nanobiotix has entered into major collaboration agreements with global pharmaceutical companies to co-develop and expand the clinical applications of its technology.
Strategic Position & Investments
Nanobiotix’s strategic direction is focused on advancing NBTXR3 toward regulatory approval in multiple solid tumor indications, including head and neck cancer and lung cancer. A key element of its strategy is combining its radioenhancer technology with existing standards of care, such as radiotherapy and immune checkpoint inhibitors, to broaden clinical utility and improve patient outcomes.
The company has made significant investments in late-stage clinical trials and has entered into high-profile strategic collaborations, including a global development and commercialization partnership with Johnson & Johnson subsidiary Janssen Pharmaceutica for certain indications. These partnerships provide non-dilutive funding, development support, and potential downstream commercialization capabilities, positioning Nanobiotix to scale its technology beyond its internal resources.
Geographic Footprint
Nanobiotix is headquartered in Europe, with its principal executive offices in France, and maintains a growing operational presence in North America through Nanobiotix Inc. The company’s clinical trials are conducted across Europe, the United States, and other international markets, reflecting a broad global development strategy.
Its geographic footprint is shaped primarily by regulatory and clinical development needs rather than commercial infrastructure, as the company remains pre-revenue from product sales. Nonetheless, its international partnerships and dual stock exchange listings provide Nanobiotix with global visibility and access to capital markets across Europe and the United States.
Leadership & Governance
Nanobiotix is led by its founder, who has maintained a long-term strategic vision centered on scientific rigor, clinical validation, and disciplined capital allocation. The leadership team combines expertise in biotechnology, clinical oncology, and global drug development, supported by a board with experience in healthcare investment and pharmaceutical operations.
Key executives include:
- Laurent Lévy – Chief Executive Officer
- Philippe Pouletty – Chairman of the Board
- Frank Morvan – Chief Financial Officer
The leadership philosophy emphasizes partnering with established pharmaceutical companies, leveraging external expertise, and maintaining a focused pipeline built around a single, differentiated technology platform.